Abstract:While protein coronas (PCs) are an important barrier in the clinical application of nanomedicines, the specific effects of PCs on nanoparticles (NPs) in vivo are unclear. Herein, we demonstrated that PCs from clinical sources greatly influenced the active targeting capacities of transferrin-modified NPs (Tf-NPs). Compared to PCs from healthy volunteers, PCs from the plasma of patients with nonsmall cell lung cancer (NSCLC) decreased the A549 uptake of Tf-NPs to a greater degree. The PC proteome revealed that this difference may be mediated by certain proteins in plasma. To attenuate the negative influence of PCs from patients, precoating Tf-NPs with PCs derived from healthy mice significantly enhanced active targeting capacities. Paclitaxel-loaded Tf-NPs with PCs derived from healthy mice showed the strongest antitumor effects in mice with NSCLC. This work illustrates the influence of PCs of ligand-modified NPs in clinical practice and proposes the use of corona-enabled active targeting for precision nanomedicine.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c03982?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c03982</a>.Details related to materials and methods; characterization of particle size and zeta (ζ) potential of bare NPs and NPs with PC (Table S1); the amount of protein adsorbed on NPs (Table S2); the most abundant proteins (top 30) identified in the PC of NPs from human sources (Table S3); the most abundant proteins (top 30) identified in the PC of NPs from murine sources (Table S4); microscopic observation of coumarin+ A549 cells (Figures S1 and S3); normalized fluorescence intensity in A549 cells (Figures S2 and S4); schematic description of the experimental design for studies of in vivo mouse PC formation (Figure S5); the intensity diameter distribution of NPs with/without in vivo mouse-derived PC (Figure S6); TEM images of NPs with/without in vivo mouse-derived PC (Figure S7); microscopy observation of coumarin+ LL/2 cells (Figures S8 and S10); the normalized fluorescence intensity in LL/2 cells (Figures S9 and S11); fluorescence intensity in organs and tumor 24 h post-injection (Figure S12); tumor size in all mouse groups (Figure S13); coomassie brilliant blue-stained SDS-PAGE gel of PCs associated with NPs (Figure S14); classification of PCs according to physiological function (Figure S15); Venn diagrams depicting the number of unique proteins identified in the in vitro-formed coronas and their respective overlap (Figure S16); Venn diagrams depicting the number of unique proteins identified in the in vivo-formed coronas and their respective overlap (Figure S17); and evaluation of NP safety and IgE concentrations in serum from all murine groups (Figure S18) (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c03982/suppl_file/nl0c03982_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Precision Nanomedicine Development Based on Specific Opsonization of Human Cancer Patient-Personalized Protein Coronas.

Guiding nanomaterials to tumors for breast cancer precision medicine: from tumor-targeting small-molecule discovery to targeted nanodrug delivery.

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

Protein Nanoparticles Directed Cancer Imaging and Therapy

Versatile Protein Coronation Approach with Multiple Depleted Serum for Creating Biocompatible, Precision Nanomedicine.

Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy

Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles

Impact of Protein Corona and PEGylation on the Accumulation and Efficacy of Lysosome-Disrupting Lipid Nanoparticles in KRAS-mutated Cancer

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Synthetic Nanocapsules with Tailored Surface Chemistry for Lung‐Specific Protein Delivery and Cancer Immunotherapy

Characterization and Biomedical Application Opportunities of the Nanoparticle's Protein Corona

The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine

Cancer Cell Membrane‐Coated Nanoparticles for Personalized Therapy in Patient‐Derived Xenograft Models

Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine

Transforming Passive into Active: Multimodal Pheophytin‐Based Carbon Dots Customize Protein Corona to Target Metastatic Breast Cancer

In situ low-immunogenic albumin-conjugating-corona guiding nanoparticles for tumor-targeting chemotherapy

Regulation of protein corona on liposomes using albumin-binding peptide for targeted tumor therapy

Labeled-protein Corona-Coated Bi2S3 Nanorods Targeted to Lysosomes for Bioimaging and Efficient Photothermal Cancer Therapy.

Prominent Enhancement of Peptide-mediated Targeting Efficiency for Human Hepatocellular Carcinomas With Composition-engineered Protein Corona on Gold Nanoparticles

The role of protein corona on nanodrugs for organ-targeting and its prospects of application

Corona of Thorns: the Surface Chemistry-Mediated Protein Corona Perturbs the Recognition and Immune Response of Macrophages